MedTrace Logo

FT576 in Subjects With Multiple Myeloma

NCT05182073 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2025-12-12

No results posted yet for this study

Summary

This is a Phase I dose-finding study of FT576 as monotherapy and in combination with the monoclonal antibody daratumumab in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage.

Conditions

Interventions

DRUG

FT576 (Allogenic CAR NK cells with BCMA expression)

Experimental Interventional Therapy: FT576 comprises allogeneic natural killer (NK) cells, derived from a clonal, CD38-knockout, human-induced pluripotent stem cell line (iPSC) that expresses anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR), high-affinity, non-cleavable CD16 (hnCD16), and IL-15/IL-15 receptor fusion protein (IL-15RF).

DRUG

Cyclophosphamide

Conditioning Agent

DRUG

Fludarabine

Conditioning Agent

DRUG

Daratumumab

Anti-CD38 Monoclonal Antibody

DRUG

Bendamustine

Conditioning Agent

Sponsors & Collaborators

Principal Investigators

  • Fate Trial Disclosure · Fate Therapeutics, Inc

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-10
Primary Completion
2024-09-20
Completion
2024-10-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05182073 on ClinicalTrials.gov